CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market ...

GSK) as part of their ongoing collaboration in COVID-19 and flu vaccine programs. InvestingPro analysis reveals that the company maintains a healthy current ratio of 2.29, with liquid assets exceeding ...

GSK)'s Phase 2 data has bolstered confidence in Arcus's own TIGIT assets. Looking ahead, Arcus Biosciences has several potential catalysts that could significantly impact its stock performance.

FORE School of Management hosted Oraculum 2025, bringing together industry leaders, policymakers and aspiring professionals ...

FORE School of Management successfully hosted Oraculum 2025, bringing together industry leaders, policymakers, and aspiring professionals for two days of thought-provoking discussions. Centered around ...

This comprehensive analysis delves into Arcus Biosciences' current position ... The superior ORR observed for TIGIT/PD-1 combination therapy versus historical standard of care PD-1 in GSK's Phase 2 ...